The purpose of this study is to evaluate the pharmacokinetic profile of Esomeprazole (D961H) during repeated oral administration with and without co-administration of loxoprofen and the pharmacokinetic profile of loxoprofen during repeated oral administration with and without co-administration of Esomeprazole (D961H).

Inclusion Criteria:

• Healthy Japanese male
• Body Mass Index (BMI=weight/height2) 19-27 (kg/m2)
• Body weight 50-80 kg

Exclusion Criteria:

• Past or present NSAIDs induced asthma, hepatic dysfunction, peptic ulcer or blood disorders
• Significant clinical illness from the 2 weeks preceding the pre-entry visit to the randomisation, as judged by the investigator(s) , eg, acute inflammatory disease which requires medical intervention
• Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease, as judged by the investigator(s), eg, sequelae of myocardial infarction, nephritis, hepatitis and cerebral infarction